Although darolutamide and proxalutamide show clinical efficacy in CRPC patients harboring point mutations within the AR LBD [40, 44], these antagonists cannot target AR variants such as AR-v7 or ARv567es that lack the LBD and contribute to prostate cancer progression and resistance to AR antagonists [93, 125–128]. This evidence concerns the gene AR and prostate cancer.